ReNeuron Group plc (LON:RENE – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 4.05 ($0.05) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares trading hands.
ReNeuron Group Price Performance
The firm’s fifty day moving average price is GBX 3.38 and its 200-day moving average price is GBX 4.05. The company has a quick ratio of 2.02, a current ratio of 1.51 and a debt-to-equity ratio of 14.25. The stock has a market cap of £1.93 million, a P/E ratio of -37.50 and a beta of 0.69.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Featured Stories
- Five stocks we like better than ReNeuron Group
- How to Find Undervalued Stocks
- Garmin Navigates to New Highs Driven By Wearables Trend
- Investing in Travel Stocks Benefits
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- How to Use High Beta Stocks to Maximize Your Investing Profits
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
